Tandem Diabetes Care Earnings Call Transcripts
Fiscal Year 2026
-
Management outlined rapid progress in shifting to the pharmacy channel, driving record gross margins and projecting further gains as pharmacy sales grow. Product launches, including Mobi tubeless and Sigi, will address both tubed and tubeless market segments, while international expansion and technology integration remain key priorities.
-
The business is undergoing a strategic transformation with a shift to a PAYGO model, expanded pharmacy access, and a robust innovation pipeline including Mobi Tubeless and a fully closed loop algorithm. These initiatives are expected to drive double-digit growth, higher margins, and improved patient access.
-
Record Q4 performance was driven by commercial transformation, new product launches, and a strategic shift to the pharmacy channel. The transition to direct sales internationally and a pay-as-you-go model in the U.S. is expected to drive recurring revenue and margin expansion, with significant growth projected for 2027.
Fiscal Year 2025
-
Achieved record 2025 results with over $1B in sales, double-digit growth, and margin expansion. 2026 guidance reflects a strategic shift to a pay-as-you-go pharmacy model, expected to drive long-term growth despite near-term headwinds, with new product launches and international expansion planned.
-
Significant Q3 revenue growth was driven by pharmacy channel expansion and pricing, with gross margins improving and a multi-year tailwind expected from further adoption. Product innovation, including a new patch pump and closed-loop system, positions the company for continued growth and market expansion.
-
Q3 2025 results met expectations, with strong pricing and pharmacy channel growth. The pipeline is robust, with tubeless Mobi and fully closed loop systems targeted for 2026. Type-2 and international markets offer significant expansion, and financial outlook includes margin and OPEX leverage improvements.
-
Record Q3 sales and margin improvements were driven by higher pricing, pharmacy channel expansion, and strong international growth. Strategic initiatives in innovation, direct sales, and operational efficiency position the business for double-digit growth and margin expansion in 2025 and beyond.
-
Aggressive expansion into the pharmacy channel and direct international sales are expected to drive double-digit growth and margin improvement. New product launches, including Tubeless Mobi and SteadySet, and a fully closed-loop algorithm, position the company for increased competitiveness and broader market adoption.
-
Significant growth opportunities exist in underpenetrated diabetes markets, with a broadened product portfolio and expansion into the pharmacy channel. Financial guidance for 2025 is set at $1 billion, with international growth offsetting U.S. headwinds. Margin improvement and new product launches, including extended-wear and patch pumps, are expected to drive future performance.
-
Record Q2 sales and margin expansion were driven by strong U.S. renewals, international growth, and pharmacy channel progress. 2025 guidance was updated to $1B in sales, with gross margin expected at 53%-54% and a return to positive free cash flow in H2.
-
Strong Q1 growth was driven by Mobi adoption and supply sales, with further expansion expected from new product launches, international direct sales, and pharmacy channel penetration. Margin improvements are anticipated as Mobi and pharmacy become larger revenue contributors, while a robust pipeline and new algorithms support long-term growth.
-
Expansion into the type 2 diabetes market and pharmacy channel is set to more than double the addressable market and drive margin growth. Mobi’s success, upcoming product innovations, and direct international operations are expected to boost penetration and profitability.
-
Strong Q1 growth was driven by MDI conversions, robust retention, and price improvements. The type two diabetes market and pharmacy channel expansion are major growth catalysts, with Mobi and new product innovations supporting margin expansion. Guidance remains conservative, with upside potential from ongoing initiatives.
-
Q1 delivered record sales and double-digit growth, driven by strong U.S. and international performance, new product launches, and expanded pharmacy access. Gross margin improved, guidance was reaffirmed, and the pipeline remains robust, with significant opportunities in type 2 diabetes and international markets.
-
Control-IQ+ received approval, expanding the market to younger and Type 2 patients with strong clinical results. Sales force and pharmacy initiatives aim to boost reach and affordability, while international sales and new launches will drive growth. Gross margin is expected to expand in 2025, with upside from new opportunities not yet in guidance.
-
Strong 2024 performance was driven by Mobi-fueled MDI growth and robust renewals, with 2025 guidance targeting double-digit U.S. revenue growth and continued OUS penetration. Product innovation, pharmacy channel expansion, and type 2 market entry are set to drive future profitability and competitive positioning.
-
Conservative 2025 guidance is supported by strong product innovation, expanded pharmacy access, and a larger, more data-driven sales force. Margin improvements and new market opportunities, especially in Type 2 diabetes, are expected to drive long-term growth.
Fiscal Year 2024
-
Achieved record 2024 sales with 18% growth, driven by new product launches and strong U.S. and international performance. 2025 guidance projects 10%-11% sales growth, margin expansion, and continued investment in innovation, with modest initial contributions from new type 2 and pharmacy initiatives.
-
Strong market growth is driven by technology innovation, new product launches like Mobi, and expanded channel access through pharmacy contracts. International expansion, high renewal rates, and a robust pipeline support future growth and margin improvement.
-
Record Q3 revenue and strong Mobi adoption are driving growth, with new pharmacy contracts and product innovations like tubeless Mobi and a fully closed-loop system in development. Type II market expansion and margin improvements are key strategic priorities.
-
Significant growth is expected in both Type 1 and Type 2 diabetes device markets, driven by new product launches, expanded sensor integrations, and entry into the pharmacy channel. Mobi's success and international expansion are fueling record revenues, with a conservative but optimistic outlook for 2025.
-
U.S. pump market growth is accelerating, driven by new product launches and untapped MDI users. Mobi pump and pharmacy channel entry are key 2025 catalysts, while Type 2 diabetes and OUS renewals offer incremental opportunities. Pipeline focus remains on sensor integration and regulatory expansion.
-
Pump shipments and new patient growth remain strong, led by Mobi, with high renewal rates and expanding opportunities in 2025 from new product launches, Type 2 diabetes, and pharmacy channel expansion. Profitability is set to improve as Mobi becomes accretive and pipeline initiatives advance.
-
Record sales and strong new patient growth were achieved, driven by Mobi pump adoption and international expansion. Strategic focus remains on margin improvement, product innovation, and capturing renewal and Type 2 diabetes opportunities, with no formal 2025 guidance yet.
-
Record Q3 sales and strong operational performance were driven by new product launches and expanding market access. Guidance for 2024 was raised, with continued growth expected from new products, pharmacy channel expansion, and type 2 diabetes opportunities.
-
Insulin pump adoption remains underpenetrated, with strong growth potential in both Type 1 and Type 2 diabetes. Recent product launches, especially Mobi, are expanding the addressable market, while cost efficiencies and new channel strategies support long-term margin and cash flow goals.
-
Mobi's strong launch is driving new user growth, especially among MDI switchers, while Sigi and integration with FreeStyle Libre 3 expand the product portfolio. Type 2 market penetration is expected to rise significantly, supported by clinical trials and regulatory efforts. Gross margin improvements and new business models are key financial priorities.
-
Management outlined a multi-product strategy with Mobi as a key growth driver, raised 2024 guidance to 15% growth, and expects gross margin improvement from new products and pharmacy channel expansion. Type 2 market penetration and international renewals are set to boost growth in 2025.
-
A user-focused, multi-device portfolio is driving strong growth, with Mobi expanding the market by converting MDI users and boosting Q2 results. Upcoming Type 2 FDA submission and operational efficiencies are expected to further improve margins and global penetration.
-
Q2 2024 saw 12% sales growth, driven by strong demand for new products like Tandem Mobi, which attracted new and younger customers. Gross margin reached 51%, and guidance was raised to 15% annual growth, with positive trends in both U.S. and international markets.
-
Significant growth is expected in the diabetes pump market, driven by recent product launches, strong feedback for Mobi, and expanded sensor integrations. International expansion, pharmacy channel entry, and a robust innovation pipeline are set to drive future profitability and market share.